Perspectives for novel mixed diruthenium-organic drugs as metallopharmaceuticals in cancer therapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 4, 2010, Pages 312-323

  De Oliveira Silva, Denise ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anticancer activity; Antitumor metallodrugs; Coordination compounds; Glioma; Medicinal chemistry; Non steroidal antiinflammatory drugs; Ruthenium compounds

Indexed keywords

INDAZOLIUM TETRACHLOROBIS(INDAZOLE)RUTHENATE; NAMI A; RUTHENIUM COMPLEX; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CLINICAL TRIAL; DRUG STRUCTURE; GLIOBLASTOMA; HUMAN; NONHUMAN; REVIEW;

EID: 77951657184     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152010791162333     Document Type: Review

References (167)

1. Jones, C. J.; Thornback, J. R. Medicinal Applications of Coordination Chemistry; RSC Publishing: Cambridge, 2005.
2. Gielen, M.; Tiekink, E.R.T. Metallotherapeutic Drugs & Metalbased Diagnostic Agents- The Use of Metals in Medicine; John Wiley & Sons Ltd.: West Sussex, 2005.
3. van Rijt, S. H.; Sadler, P. J. Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. Drug Discov. Today, 2009, 14, 1089-1097.
4. Ronconi, L.; Sadler, P. J. Using coordination chemistry to design new medicines. Coord. Chem. Rev., 2007, 251, 1633-1648.
5. Jakupec, M. A.; Galanski, M.; Arion, V. B.; Hartinger, C. G.; Keppler, B. K. Antitumor metal compounds: more than theme and variations. Dalton Trans., 2008, 2, 183-194.
6. Gianferrara, T.; Bratsos, I.; Alessio, E. A categorization of metal anticancer compounds based on their mode of action. Dalton Trans., 2009, 37, 7588-7598.
7. Ang, W. H.; Dyson, P. J. Classical and non-classical rutheniumbased anticancer drugs: towards targeted chemotherapy. Eur. J. Inorg. Chem., 2006, 20, 4003-4018.
8. Rosenberg, B.; Vancamp, L. V.; Trosko, J. E.; Mansour, V. H. Platinum compounds: a new class of potent antitumor agent. Nature, 1969, 222, 385-386.
9. Wong, E.; Giandomenico, C. M. Current status of platinum-based antitumor drugs. Chem Rev., 1999, 99, 2451-2466.
10. Wang, D.; Lippard, S. J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov., 2005, 4, 307-320.
11. Brabec, V.; Kasparkova, J. Modifications of DNA by platinum complexes -Relation to resistance of tumors to platinum antitumor drugs. Drug Res. Updates, 2005, 8, 131-146.
12. Lovejoy, K. S.; Lippard, S. J. Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting. Dalton Trans., 2009, 48, 10651-10659.
13. Brabec, V.; Kasparkova, J. 78Pt Platinum-based Drugs. In: Metallotherapeutic Drugs & Metal-based Diagnostic Agents- The Use of Metals in Medicine, Gielen, M.; Tiekink, E.R.T., Eds. John Wiley & Sons Ltd.: West Sussex, 2005; pp. 490-506.
14. Reedijk, J. Platinum anticancer coordination compounds: Study of DNA binding inspires new drug design. Eur. J. Inorg. Chem., 2009, 10, 1303-1312.
15. Burger, K. N. J.; Staffhorst, R. W. H. M.; De Vijlder, H. C.; Velinova, M. J.; Bomans, P. H.; Frederik, P. M.; De Kruijff, B. Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity. Nat. Med., 2002, 8, 81-84.
16. 44Ru Perspectives of ruthenium complexes in cancer theraphy. In: Metallotherapeutic Drugs & Metal-based Diagnostic Agents - The use of metals in medicine, Gielen, M.; Tiekink, E.R.T., Eds. John Wiley & Sons Ltd.: West Sussex, 2005; pp. 359-378.
17. Kostova, I. Ruthenium complexes as anticancer agents. Curr. Med. Chem., 2006, 13, 1085-1107.
18. Bergamo, A.; Sava, G. Ruthenium complexes can target determinants of tumor malignancy. Dalton Trans., 2007, 13, 1267-1272.
19. Levina, A.; Mitra, A.; Lay, P. A. Recent developments in ruthenium anticancer drugs. Metallomics, 2009, 1, 458-470.
20. Fink, G. S. Arene ruthenium complexes as anticancer agents. Dalton Trans., 2010, 39, 1673-1688.
21. Carter, D. C.; Ho, J. X., Structure of serum albumin. Adv. Protein Chem., 1994, 45, 153-203.
22. Sun, H.; Li, H.; Sadler, P. J. Transferrin as a metal ion mediator. Chem. Rev., 1999, 99, 2817-2842.
23. Timerbaev, A. R.; Hartinger, C. G.; Aleksenko, S. S.; Keppler, B. K. Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. Chem. Rev., 2006, 106, 2224-2248.
24. Reisner, E.; Arion, V. B.; Keppler, B. K.; Pombeiro, A. J. L. Electron-transfer activated metal-based anticancer drugs. Inorg. Chim. Acta, 2008, 361, 1569-1583.
25. Huheey, J. E.; Keiter, E. A.; Keiter, R. L. Inorganic Chemistry: Principles of Structure and Reactivity; 4th ed. Happer Collins College Publishers: New York, 1993.
26. Varmus, H. The new era in cancer research. Science, 2006, 312, 1162-1165.
27. Dyson, P. J.; Sava, G. Metal-based antitumor drugs in the post genomic era. Dalton Trans., 2006, 16, 1929-1933.
28. Clarke, M. J. Ruthenium complexes: potential roles in anticancer pharmaceutics. In: Metal Complexes in Cancer Chemotherapy, Keppler, B. K., Ed. VCH: New York, 1993; pp.129-156.
29. Clarke, M. J. Ruthenium metallopharmaceutics. Coord. Chem. Rev., 2003, 236, 209-233.
30. Mestroni, G.; Alessio, E.; Sava, G.; Pacor, S.; Coluccia, M. The Development of Tumor-Inhibiting Ruthenium-Dimethylsulfoxide Complexes. In: Metal Complexes in Cancer Chemotherapy, Keppler, B. K., Ed. VCH: New York, 1993; pp.157-185.
31. 4 X; = CI, Br): Synthesis, structure, and antitumor activity. Inorg. Chem., 1988, 27, 4099-4106.
32. Sava, G.; Pacor, S.; Zorzet, S.; Alessio, E.; Mestroni, G. Antitumor properties of dimethylsulphoxide ruthenium(II) complexes in the lewis lung carcinoma system. Pharmacol. Res., 1989, 21, 617-628.
33. Coluccia, M.; Sava, G.; Loseto, F.; Nassi, A.; Boccarelli, A.; Giordano, D.; Alessio, E.; Mestroni, G. Anti-leukaemic action of RuCl2(DMSO)4 isomers and prevention of brain involvement on P388 leukaemia and on P338/DDP subline. Eur. J. Cancer, 1993, 29A, 1873-1879.
34. Cabrera, E.; Cerecetto, H.; Gonzalez, M.; Gambino, D.; Noblia, P.; Otero, L.; Parajon-Costa, B.; Anzellotti, A.; Sanchez-Delgado, R.; Azqueta, A.; de Cerain, A. L.; Monge, A. Ruthenium(II) nitrofurylsemicarbazone complexes: new DNA binding agents. Eur. J. Med. Chem., 2004, 39, 377-382.
35. Wu, A.; Kennedy, D. C.; Patrick, B. O.; James, B. R. Ruthenium(II) sulfoxide-maltolato and -nitroimidazole complexes: Synthesis and MTT assay. Inorg. Chem., 2003, 42, 7579-7586.
36. Toma, H. E.; De Oliveira Silva, D. Chromatographic, spectroscopic and electrochemical characterization of geometrical isomers of the diclorobis(2,6-dimethylpyrazine bis(dimethylsulphoxide)ruthenium (II) complex. Polyhedron, 1991, 10, 1699-1704.
37. Toma, H. E.; De Oliveira Silva, D. Elution behavior of Nheterocyclic derivatives of mixed ruthenium(II)-sulfoxide complexes in reversed-phase high performance liquid chromatography. Chromatographia, 1991, 32, 546-548.
38. De Oliveira Silva, D.; Toma, H. E. Linkage isomerization and electrochemical behavior of two geometrical isomers of dichlorobis( dimethylsulfoxide)bis(t-butylpyridine)ruthenium(II). Can. J. Chem., 1994, 72, 1705-1708.
39. De Oliveira Silva, D.; Saika, J. J.; Toma, H. E. Photochemical behavior of the dichlorobis(dimethylsulfoxide)bis(t-butylpyridine) ruthenium(II) complex. J. Photochem. Photobiol. A: Chem., 1998, 112, 209-212.
40. Brindell, M.; Kulis, E.; Elmroth, S. K. C.; Urbanska, K.; Stochel, G. Light-Induced anticancer activity of [RuCl2(DMSO)4] complexes. J. Med. Chem. 2005, 48, 7298-7304.
41. 2], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B. J. Inorg. Biochem., 2010, 104, 111-117.
42. Keppler, B. K.; Lipponer, K.; Stenzel, B.; Kratz, F. New tumor-inhibiting ruthenium complexes. In: Metal Complexes in Cancer Chemotherapy, Keppler, B. K., Ed.; VCH: New York, 1993; pp.187-220.
43. Bratsosa, I.; Jednera, S.; Gianferrara, T.; Alessio, E. Ruthenium anticancer compounds: challenges and expectations. Chimia, 2007, 61, 692-697.
44. Alessio, E.; Mestroni, G.; Bergamo, A.; Sava, G. Ruthenium antimetastatic agents. Curr. Top. Med. Chem., 2004, 4, 1525-1535.
45. Cocchietto, M.; Zorzet, S.; Sorc, A.; Sava, G. Primary tumor, lung and kidney retention and antimetastasis effect of NAMI-A following different routes of administration. Invest. New Drugs, 2003, 21, 55-62.
46. Sava, G.; Capozzi, I.; Clerici, K.; Gagliardi, G.; Alessio, E.; Mestroni, G. Pharmacological control of lung metastases of solid tumors by a novel ruthenium complex. Clin. Exp. Metastasis, 1998, 16, 371-379.
47. Sava, G.; Bergamo, A.; Zorzet, S.; Gava, B.; Casarsa, C.; Cocchietto, M.; Furlani, A.; Scarcia, V.; Serli, B.; Iengo, E.; Alessio, E.; Mestroni, G. Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A. Eur. J. Cancer, 2002, 38, 427-435.
48. Bergamo, A.; Gagliardi, R.; Scarcia, V.; Furlani, A.; Alessio, E.; Mestroni, G.; Sava, G. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin J. Pharmacol. Exp. Ther., 1999, 289, 559-564.
49. Sava, G.; Zorzet, S.; Turrin, C.; Vita, F.; Soranzo, M. R.; Zabucchi, G.; Cocchietto, M.; Bergamo, A.; DiGiovine, S.; Pezzoni, G.; Sartor, L.; Garbisa, S. Dual action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen. Clin. Cancer Res., 2003, 9, 1898-1905. (Pubitemid 36554618)
50. Frausin, F.; Cocchietto, M.; Bergamo, A.; Searcia, V.; Furlani, A.; Sava, G. Tumor cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells. Cancer Chemother. Pharmacol., 2002, 50, 405-411. (Pubitemid 35440529)
51. Sava, G.; Pacor, S.; Zorzet, S.; Alessio, E.; Mestroni, G. Antitumor properties of dimethylsulphoxide ruthenium(II) complexes in the lewis lung carcinoma system. Pharmacol. Res., 1989, 21, 617-628. (Pubitemid 19250108)
52. 4 isomers and prevention of brain involvement on P388 leukaemia and on P338/DDP subline. Eur. J. Cancer, 1993, 29A, 1873-1879.
53. Cabrera, E.; Cerecetto, H.; Gonzalez, M.; Gambino, D.; Noblia, P.; Otero, L.; Parajon-Costa, B.; Anzellotti, A.; Sanchez-Delgado, R.; Azqueta, A.; de Cerain, A. L.; Monge, A. Ruthenium(II) nitrofurylsemicarbazone complexes: new DNA binding agents. Eur. J. Med. Chem., 2004, 39, 377-382. (Pubitemid 38457031)
54. Wu, A.; Kennedy, D. C.; Patrick, B. O.; James, B. R. Ruthenium(II) sulfoxide-maltolato and -nitroimidazole complexes: Synthesis and MTT assay. Inorg. Chem., 2003, 42, 7579-7586.
55. Toma, H. E.; De Oliveira Silva, D. Chromatographic, spectroscopic and electrochemical characterization of geometrical isomers of the diclorobis(2,6-dimethylpyrazine bis(dimethylsulphoxide)ruthenium (II) complex. Polyhedron, 1991, 10, 1699-1704.
56. Toma, H. E.; De Oliveira Silva, D. Elution behavior of N-heterocyclic derivatives of mixed ruthenium(II)-sulfoxide complexes in reversed-phase high performance liquid chromatography. Chromatographia, 1991, 32, 546-548.
57. De Oliveira Silva, D.; Toma, H. E. Linkage isomerization and electrochemical behavior of two geometrical isomers of dichlorobis(dimethylsulfoxide)bis(t-butylpyridine)ruthenium(II). Can. J. Chem., 1994, 72, 1705-1708.
58. De Oliveira Silva, D.; Saika, J. J.; Toma, H. E. Photochemical behavior of the dichlorobis(dimethylsulfoxide)bis(t-butylpyridine) ruthenium(II) complex. J. Photochem. Photobiol. A: Chem., 1998, 112, 209-212.
59. Brindell, M.; Kulis, E.; Elmroth, S. K. C.; Urbanska, K.; Stochel, G. Light-Induced anticancer activity of [RuCl2(DMSO)4] complexes. J. Med. Chem. 2005, 48, 7298-7304.
60. 2], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B. J. Inorg. Biochem., 2010, 104, 111-117.
61. Keppler, B. K.; Lipponer, K.; Stenzel, B.; Kratz, F. New tumorinhibiting ruthenium complexes. In: Metal Complexes in Cancer Chemotherapy, Keppler, B. K., Ed.; VCH: New York, 1993; pp.187-220.
62. Bratsosa, I.; Jednera, S.; Gianferrara, T.; Alessio, E. Ruthenium anticancer compounds: challenges and expectations. Chimia, 2007, 61, 692-697.
63. Alessio, E.; Mestroni, G.; Bergamo, A.; Sava, G. Ruthenium antimetastatic agents. Curr. Top. Med. Chem., 2004, 4, 1525-1535.
64. Cocchietto, M.; Zorzet, S.; Sorc, A.; Sava, G. Primary tumor, lung and kidney retention and antimetastasis effect of NAMI-A following different routes of administration. Invest. New Drugs, 2003, 21, 55-62. (Pubitemid 36628485)
65. Sava, G.; Capozzi, I.; Clerici, K.; Gagliardi, G.; Alessio, E.; Mestroni, G. Pharmacological control of lung metastases of solid tumors by a novel ruthenium complex. Clin. Exp. Metastasis, 1998, 16, 371-379. (Pubitemid 28255532)
66. Sava, G.; Bergamo, A.; Zorzet, S.; Gava, B.; Casarsa, C.; Cocchietto, M.; Furlani, A.; Scarcia, V.; Serli, B.; Iengo, E.; Alessio, E.; Mestroni, G. Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A. Eur. J. Cancer, 2002, 38, 427-435. (Pubitemid 34123316)
67. Bergamo, A.; Gagliardi, R.; Scarcia, V.; Furlani, A.; Alessio, E.; Mestroni, G.; Sava, G. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin J. Pharmacol. Exp. Ther., 1999, 289, 559-564. (Pubitemid 29156075)
68. Sava, G.; Zorzet, S.; Turrin, C.; Vita, F.; Soranzo, M. R.; Zabucchi, G.; Cocchietto, M.; Bergamo, A.; DiGiovine, S.; Pezzoni, G.; Sartor, L.; Garbisa, S. Dual action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen. Clin. Cancer Res., 2003, 9, 1898-1905. (Pubitemid 36554618)
69. Frausin, F.; Cocchietto, M.; Bergamo, A.; Searcia, V.; Furlani, A.; Sava, G. Tumor cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells. Cancer Chemother. Pharmacol., 2002, 50, 405-411. (Pubitemid 35440529)
70. Dyson, P. J. Systematic design of a targeted organometallic antitumor drug in pre-clinical development. Chimia, 2007, 61, 698-703.
71. Dale, L. D.; Tocher, J. H.; Dyson, T. M.; Edwards, D. I.; Tocher, D. A. Studies on DNA damage and induction of SOS repair by novel multifunctional bioreducible compounds.2. A metronidazole adduct of a ruthenium-arene compound. Anti-Cancer Drug Des., 1992, 7, 3-14.
72. Yan, Y. K.; Melchart, M.; Habtemariam, A.; Sadler, P. J. Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes. Chem. Commun., 2005, 38, 4764-4776.
73. John, R. O.; Arion, V. B.; Jakupec, M. A.; Keppler, B. K. Ruthenium(II)-arene complex with heterocyclic ligands as prospective antitumor agent. Met. Ions Biol. Med., 2006, 9, 40-45.
74. Huxham, L. A.; Cheu, E. L. S.; Patrick, B. O.; James, B. R. The synthesis, structural characterization, and in vitro anti-cancer activity of chloro(p-cymene) complexes of ruthenium(II) containing a disulfoxide ligand. Inorg. Chim. Acta, 2003, 352, 238-246.
75. Casini, A.; Gabbiani, C.; Michelucci, E.; Pieraccini, G.; Monet, G.; Dyson, P. J.; Messori, L. Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound. J. Biol. Inorg. Chem., 2009, 14, 761-770.
76. Casini, A.; Gabbiani, C.; Sorrentino, F.; Rigobello, M. P.; Bindoli, A.; Geldbach, T. J.; Marrone, A.; Re, N.; Hartinger,C. G.; Dyson, P. J.; Messori, L. Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds. J. Med. Chem., 2008, 51, 6773-6781.
77. Bergamo, A.; Mais, A.; Peacock, A.F.A.; Habtemariam, A.; Sadler, P.J.; Sava, G. In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model. J. Inorg. Biochem., 2010, 104, 79-86.
78. Debreczeni, J. É.; Bullock, A. N.; Atilla, G. E.; Williams, D. S.; Bregman, H.; Knapp S.; Meggers, E. Ruthenium half-sandwich complexes bound to protein kinase Pim-1. Angew. Chem., Int. Ed., 2006, 45, 1580-1585. (Pubitemid 44109229)
79. Barve, V.; Ahmed, F.; Adsule, S.; Banerjee,S.; Kulkarni, S.; Katiyar, P.; Anson, C. E.; Powell, A. K.; Padhye S.; Sarkar, F.H.; Synthesis, molecular characterization, and biological activity of novel synthetic derivatives of chromen-4-one in human cancer cells. J. Med. Chem., 2006, 49, 3800-3808.
80. rd ed.; Springer Science and Busines Media, Inc.: New York, 2005.
81. Aquino, M. A. S. Diruthenium and diosmium tetracarboxylates: synthesis, physical properties and applications. Coord. Chem. Rev., 1988, 170, 141-202.
82. Aquino, M. A. S. Recent developments in the synthesis and properties of diruthenium tetracarboxylates. Coord. Chem. Rev., 2004, 248, 1025-1045.
83. Ribeiro, G.; Vichi, F. M.; de Oliveira Silva, D. Synthesis, characterization and adsorption properties of porous mixed valent diruthenium(II,III)-terephthalate and diruthenium(II,III)-adipate polymers. J. Mol. Struct., 2008, 890, 209-214.
84. Bennett, M. J.; Caulton, K. G.; Cotton, F. A. Structure of tetra-nbutyratodiruthenium chloride, a compound with a strong metalmetal bond. Inorg. Chem., 1969, 8, 1-6.
85. van Rensburg, C. E. J.; Kreft, E.; Swarts, J. C.; Dalrymple, S. R.; Macdonald, D. M.; Cooke, M. W.; Aquino, M. A. S. Cytotoxicity of a series of water-soluble mixed valent diruthenium tetracarboxylates. Anticancer Res., 2002, 22, 889-892.
86. Dunbar, K. R.; Matonic, J. H.; Saharan,V. P.; Crawford, C. A.; Christou, G. Structural evidence for a new metal-binding mode for guanine bases: implications for the binding of dinuclear antitumor agents to DNA. J. Am. Chem. Soc., 1994, 116, 2201-2202. (Pubitemid 24249865)
87. Crawford, C. A.; Day, E. F.; Saharan, V. P.; Folting, K.; Huffman, J. C.; Dunbar, K. R.; Christou G. N-7,O-6 bridging 9-ethylguanine (9-EtGH) groups in dinuclear metal-metal bonded complexes with bond orders of one, two or four. J. Chem. Soc., Chem. Commun., 1996, 1113-1114. (Pubitemid 26171717)
88. th ed.; Lippincott Williams & Wilkins: New York, 1995.
89. Griffin, M. R.; Sheiman, J. M. Prospects for changing the burden of nonsteroidal anti-inflammatory drug toxicity. Am. J. Med., 2001, 110, S33-S37.
90. Vane, J. R.; Flower, R. J.; Botting, R. M. History of aspirin and its mechanism of action. Stroke, 1990, 21, 12-23.
91. Herendeen, J. M.; Lindley, C. Use of NSAIDs for the chemioprevention of colorectal cancer. Ann. Pharmacother., 2003, 37, 1664-1674.
92. Pereg D.; Lishner, M. Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J. Int. Med., 2005, 258, 115-123.
93. Thun, M. J.; Henley, S. J.; Patrono, C. Nonsteroidal antiinflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Nat. Cancer Inst., 2002, 94, 252-266.
94. Gupta, R. A.; DuBois, R. N. Aspirin, NSAIDS, and colon cancer prevention: mechanisms? Gastroenterology, 1998, 114, 1095-1098.
95. Rao, C. V.; Reddy, B.S. NSAIDs and chemoprevention. Curr. Cancer Drug Targets, 2004, 4, 29-42.
96. Giovannucci, E.; Egan, K. M.; Hunter, D. J.; Stampfer, M. J.; Colditz, G. A.;Willett,W. C.; Speizer, F. E. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med., 1995, 333, 609-614.
97. Farrow, D. C.; Vaughan, T. L.; Hansten, P. D.; Stanford, J. L.; Risch, H. A.; Gammon, M. D.; Chow, W. H.; Dubrow, R.; Ahsan, H.; Mayne, S. T.; Schoenberg, J. B.; West, A. B.; Rotterdam, H.; Fraumeni Jr, J. F.; Blot, W. J. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomarkers Prev., 1998, 7, 97-102.
98. Akre, K.; Ekstrom, A. M.; Signorello, L. B.; Hansson, L. E.; Nyren, O. Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. Br. J. Cancer, 2001, 84, 965-968.
99. Baron, J. A.; Sandler, R. S. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu. Rev. Med., 2000, 51, 511-523.
100. Dai, Y.; Wang, W. H. Non-steroidal anti-inflammatory drugs in prevention of gastric cancer. World. J. Gastroenterol., 2006, 12, 2884-2889.
101. Zaridze, D.; Borisova, E.; Maximovitch, D.; Chkhikvadze, V. Aspirin protects against gastric cancer: results of a case-control study from Moscow, Russia. Int. J. Cancer, 1999, 82, 473-476.
102. Greenberg, E. R.; Baron, J. A.; Freeman, D. H. Jr.; Mandel, J. S.; Haile, R. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J. Natl. Cancer Inst., 1993, 85, 912-916.
103. Dube, C.; Rostom, A.; Lewin, G.; Tsertsvadze, A.; Barrowman, N.; Code, C.; Sampson, M.; Moher, D. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann. Intern. Med., 2007, 146, 365-375.
104. Gridley, G.; McLaughlin, J. K.; Ekbom, A.; Klareskog, L.; Adami, H. O.; Hacker, D. G.; Hoover, R.; Fraumeni, J. F. Jr. Incidence of cancer among patients with rheumatoid arthritis. J. Natl. Cancer Inst., 1993, 85, 307-311.
105. Wang, W. H.; Huang, J. Q.; Zheng,G. F.; Lam, S. K.; Karlberg, J.; Wong, B. C. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J. Natl. Cancer Inst., 2003, 95, 1784-1791.
106. Schreinemachers, D. M.; Everson, R. B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology, 1994, 5, 138-146.
107. Tanaka, T.; Kojima, T.; Yoshimi, N.; Sugie, S.; Mori, H. Inhibitory effect of the non-steroidal anti-inflammatory drug, indomethacin on the naturally occurring carcinogen, 1-hydroxyanthraquinone in male ACI/N rats. Carcinogenesis, 1991, 12, 1949-1952.
108. Hu, P. J.; Yu, J.; Zeng, Z. R.; Leung, W. K.; Lin, H. L.; Tang, B. D.; Bai, A. H.; Sung, J. J. Chemoprevention of gastric cancer by celecoxib in rats. Gut, 2004, 53, 195-200.
109. Sawaoka, H.; Kawano, S.; Tsuji, S.; Tsujii, M.; Gunawan, E. S.; Takei, Y.; Nagano, K.; Hori, M. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am. J. Physiol., 1998, 274, 1061-1067.
110. Beazer-Barclay, Y.; Levy, D. B.; Moser, A. R.; Dove, W. F.; Hamilton, S. R.; Vogelstein, B.; Kinzler, K. W. Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis, 1996, 17, 1757-1760.
111. Harris, R. E.; Kasbari, S.; Farrar, W. B. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol. Rep., 1999, 6, 71-73.
112. Hida, T.; Leyton, J.; Makheja, A.,N.; Ben-Av, P.; Hla, T.; Martinez, A.; Mulshine, J.; Malkani, S.; Chung, P.; Moody, T.W. Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs. Anticancer Res., 1998, 18, 775-782.
113. Chan, T. A. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol., 2002, 3, 166-174.
114. Chan, T. A.; Morin, P. J.; Vogelstein, B.; Kinzler, K. W. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc. Natl. Acad. Sci. USA, 1998, 95, 681-686.
115. Fitzgerald, G. A. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discov., 2003, 2, 879-891.
116. Jana, N. R. NSAIDs and apoptosis. Cell. Mol. Life Sci., 2008, 65, 1295-2130
117. Shiff, S. J.; Koutsos, M. I.; Qiao, L.; Rigas, B. Nonsteroidal anti inflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Expl. Cell Res., 1996, 222, 179-188. (Pubitemid 26043724)
118. Smith, M. L.; Hawcroft, G.; Hull, M. A. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur. J. Cancer, 2000, 36, 664-674.
119. Green, D. R.; Kroemer, G. The pathophysiology of mitochondrial cell death. Science, 2004, 305, 626-629.
120. Green, D. R. Apoptotic pathways: ten minutes to dead. Cell, 2005, 121, 671-674.
121. Green, D. R.; Kroemer, G. Pharmacological manipulation of cell death: clinical applications in sight? J. Clin. Invest., 2005, 115, 2610-2617.
122. th Ed.; John Wiley & Sons, Inc.: New York, 1997.
123. Sorenson, J. R. J. Biology of Copper Complexes; Humana Press: New York, 1987.
124. Weder, J. E.; Dillon, C. T.; Hambley, T. W.; Kennedy, B. J.; Lay, P. A.; Biffin, J. R.; Regtop, H. L. N.; Davies, M. Copper complexes of non-steroidal anti-inflammatory drugs: an opportunity yet to be realized. Coord. Chem. Rev., 2002, 232, 95-126.
125. Cotton, F. A.; De Oliveira Silva, D. Preparation and crystal structure of a dimolybdenum(II) complex with the drug ibuprofen. Inorg. Chim. Acta, 1996, 249, 57-61.
126. Carvill, A.; Higgins, P.; McCann, M.; Ryan, H.; Shiels, A. Synthesis, spectroscopic, electrochemical, and magnetic properties of dimolybdenum(II,II), diruthenium-(II,III) and -(II,II) complexes containing bridging aspirinate (2-acetoxybenzoate) ligands. J. Chem. Soc. Dalton Trans, 1989, 2435-2441.
127. Andrade, A.; Namora, S. F.; Woisky, R.G.; Wiezel, G.; Najjar, R.; Sertié, J. A. A.; De Oliveira Silva, D. Synthesis and characterization of a diruthenium-ibuprofenato complex Comparing its anti-inflammatory activity with that of a copper(II)-ibuprofenato complex. J. Inorg. Biochem., 2000, 81, 23-27.
128. Willians, D. A.; Walz, D.R.; Foye, W.O. Synthesis and biological evaluation of tetrakis(acetylsalicylato)-μ-dicopper(II). J. Pharm. Sci., 1976, 65, 126-128.
129. Oga, S.; Taniguchi, S.F.; Najjar, R.; Souza, A. R. Synthesis, characterization, and biological screening of a copper flurbiprofen complex with antiinflammatory effects. J. Inorg. Biochem., 1991, 41, 45-51.
130. Dendrinou-Samara, C.; Tsotsou, G.; Ekateriniadou, L.V.; Korsaris, A. H.; Raptopoulou, C. P.; Terzis, A.; Kyriakidis, D. A.; Kessissoglou, D. P. Anti-inflammatory drugs interacting with Zn(II), Cd(II) and Pt(II) metal ions. J. Inorg. Biochem., 1998, 71, 171-179.
131. Boyle, E.; Freeman, P. C.; Goudie, A. C.; Magan, F. R.; Thompson, M. Role of copper in preventing gastrointestinal damage by acidic anti-inflammatory drugs. J. Pharm. Pharmacol., 1976, 28, 865-868.
132. Gordijo, C. R.; Barbosa, C. A. S.; Ferreira, A. M. C.; Constantino, V. R. L.; De Oliveira Silva, D. Immobilization of ibuprofen and copper-ibuprofen drugs on layered double hydroxides. J. Pharm. Sci., 2005, 94, 1135-1148.
133. Grguric-Sipka, S. R.; Vilaplana, R. A.; Pérez, J. M.; Fuertes, M. A.; Alonso, C.; Alvarez, Y.; Sabo, T. J.; Vílchez-González, F. Synthesis, characterization, interaction with DNA and cytotoxicity of the new potential antitumour drug cis-K[Ru(eddp)Cl2]. J. Inorg. Biochem., 2003, 97, 215-220.
134. Bergamo, A.; Stocco, G.; Gava, B.; Cocchietto, M.; Alessio, E.; Serli, B.; Iengo, E.; . Sava, G. Distinct effects of dinuclear ruthenium(III) complexes on cell proliferation and on cell cycle regulation in human and murine tumor cell lines. J. Pharmacol. Expl. Ther., 2003, 305, 725-732.
135. 2O is toxic to C6 astrocytoma cell line, but not to primary rat astrocytes. J. Inorg. Biochem., 2004, 98, 2168-2173.
136. Lefranc, F.; Brotchi, J.; Kiss, R. Possible future issues in the treatment of glioblastomas: Special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J. Clin. Oncol., 2005, 23, 2411-2422.
137. Giese, A.; Bjerkvig, R.; Berens, M. E., Westphal, M. Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol., 2003, 21,1624-1636.
138. Maher, E. A.; Furnari, F. B.; Bachoo, R. M.; Rowitch, D. H.; Louis, D. N.; Cavenee, W. K.; DePinho, R. A. Malignant glioma: genetics and biology of a grave matter. Genes Dev., 2001, 15, 1311-1333.
139. Zha, S.; Yegnasubramanian, V.; Nelson, W. G.; Isaacs, W. B.; De Marzo, A. M. Cyclooxygenases in cancer: progress and perspective. Cancer Lett., 2004, 213, 1-20.
140. Shono, T.; Tofilon, P. J.; Bruner, J. M.; Owolabi, O.; Lang, F. F. Cyclooxygenase-2 expression in human gliomas: Prognostic significance and molecular correlations. Cancer Res., 2001, 61, 4375-4381.
141. Kürzel, F.; Hagel, C.; Zapf, S.; Meissner, H.; Westphal, M.; Geise, A. Cyclo-oxygenase inhibitors and thromboxane synthase inhibitors differentially regulate migration arrest, growth inhibition and apoptosis in human glioma cells. Acta Neurochir., 2002, 144, 71-87.
142. Nathoo, N.; Barnett, G. H.; Golubic, M. The eicosanoid cascade: possible role in gliomas and meningiomas. J. Clin. Pathol., 2004, 57, 6-13.
143. Wang, M.; Yoshida, D.; Liu, S.; Teramoto, A. Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index. J. Neuro Oncol., 2005, 72, 231-238.
144. Drappatz, J.; Wen, P. Non-cytotoxic drugs as potential treatments for gliomas. Curr. Opin. Neurol., 2004, 17, 663-673.
145. Tuettenberg, J.; Grobholz, R.; Korn, T.; Wenz, F.; Rever, R.; Vajkoczy, P. Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J. Cancer Res. Clin. Oncol., 2005, 131, 31-40. (Pubitemid 40064455)
146. Ferguson, S.; Lesniak, M. S. Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors. Curr. Drug Deliv., 2007, 4, 169-180.
147. Wen, P.Y.; Kesari, S.; Drappatz, J. Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment. Expert Rev. Anticancer Ther., 2006, 6, 733-754. (Pubitemid 44192889)
148. Jiang, H.; Alonso, M. M.; Gomez-Manzano, C.; Piao, Y.; Fueyo, J. Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas. Expert Rev. Anticancer Ther., 2006, 6, 1585-1592. (Pubitemid 44883961)
149. Kim, L.; Glantz, M. Chemotherapeutic options for primary brain tumors. Curr. Treat. Options Oncol., 2006, 7, 467-478. (Pubitemid 44697784)
150. Tuettenberg, J.; Friedel, C.; Vajkoczy, P. Angiogenesis in malignant glioma-a target for antitumor therapy? Crit. Rev. Oncol. Hematol., 2006, 59, 181-193.
151. Begin, M.E.; Ells, G.; Das, U. N.; Horrobin DF. Differential killing of human carcinoma cells supplemented with n-3 and n-6 polyun-saturated fatty acids. J. Natl. Cancer Inst., 1986, 77, 1053-1062.
152. Das, U. N. Essential fatty acids, lipid peroxidation and apoptosis. Prostaglandins Leukot. Essent. Fatty Acids, 1999, 61, 157-163.
153. Naidu, M. R.; Das, U. N.; Kishan, A. Intratumoral gamma-linoleic acid therapy of human gliomas. Prostaglandins Leukot. Essent. Fatty Acids, 1992, 45, 181-184.
154. Das, U. N.; Prasad, V. V.; Reddy, D. R. Local application of gamma-linolenic acid in the treatment of human gliomas. Cancer Lett., 1995, 94, 147-155.
155. Leaver, H. A.; Wharton, S. B.; Bell, H. S.; Leaver-Yap, I. M.; Whittle, I. R. Highly unsaturated fatty acid induced tumor regression in glioma pharmacodynamics and bioavailability of gamma linolenic acid in an implantation glioma model: effects on tumor biomass, apoptosis and neuronal tissue histology. Prostaglandins Leukot. Essent. Fatty Acids, 2002, 67,283-292.
156. Bakshi, A.; Mukherjee, D.; Bakshi, A.; Banerji, A. K.; Das, U. N. Gammalinolenic acid therapy of human gliomas. Nutrition, 2003, 19, 305-309.
157. Leaver, H. A.; Williams, J. R.; Smith, C.; Whittle, I. R. Intracellular oxidation by human glioma cell populations: effect of arachidonic acid. Prostaglandins Leukot. Essent. Fatty Acids, 2004, 70, 449-453.
158. Das, U. N. From bench to the clinic: gamma-linolenic acid therapy of human gliomas. Prostaglandins Leukot. Essent. Fatty Acids, 2004, 70, 539-552.
159. Colquhoun, A.; Schumacher, R. I. Gamma-linolenic acid and eicosapentaenoic acid induce modifications in mitochondrial metabolism, reactive oxygen species generation, lipid peroxidation and apoptosis in Walker 256 rat carcinosarcoma cells. Biochim. Biophys. Acta, 2001, 1533, 207-219.
160. Colquhoun, A.; Schumacher, R. I. Modifications in mitochondrial metabolism and ultrastructure and their relationship to tumor growth inhibition by gamma-linolenic acid. Mol. Cell Biochem, 2001, 218, 13-20.
161. Colquhoun, A. Gamma-linolenic acid alters the composition of mitochondrial membrane subfractions, decreases outer mitochondrial membrane binding of hexokinase and alters carnitine palmitoyltransferase I properties in the Walker 256 rat tumor. Biochim. Biophys. Acta, 2002, 1583, 74-84.
162. Ramos, K. L.; Colquhoun, A. Protective role of glucose-6-phosphate dehydrogenase activity in the metabolic response of C6 rat glioma cells to polyunsaturated fatty acid exposure. Glia, 2003, 43, 149-166. (Pubitemid 36897276)
163. Vartak, S.; Robbins, M. E.; Spector, A. A. Polyunsaturated fatty acids increase the sensitivity of 36B10 rat astrocytoma cells to radiationinduced cell
164. Vartak, S.; McCaw, R.; Davis, C. S.; Robbins, M. E.; Spector, A. A. Gammalinolenic acid (GLA) is cytotoxic to 36B10 malignant rat astrocytoma cells but not to 'normal' rat astrocytes. Br. J. Cancer, 1998, 77, 1612-1620.
165. Benadiba, M.; Miyake, J. A.; Colquhoun, A. Gamma-linolenic acid alters Ku80, E2F1, and bax expression and induces micronucleus formation in C6 glioma cells in vitro. IUBMB Life, 2009, 61, 244-251.
166. Ribeiro, G.; Benadiba, M.; Colquhoun, A.; de Oliveira Silva, D. Diruthenium (II,III) complexes of ibuprofen, aspirin, naproxen and indomethacin nonsteroidal anti-inflammatory drugs: synthesis, characterization and their effects on tumor-cell proliferation. Polyhedron, 2008, 27, 1131-1137.
167. 4Cl] inhibits C6 rat glioma cell proliferation and induces changes in mitochondrial membrane potential, increased reactive oxygen species generation and apoptosis in vitro. Cell Biochem. Funct., 2010, 28, 15-23.